AstraZeneca has sued Pharmacor over its plans to list a generic version of blockbuster diabetes drug Forxiga on the PBS, but the drug maker will have to defend the validity of the patent, which was struck down by a UK court last year.
A tax specialist has made the jump to Corrs Chambers Westgarth, after more than a decade at Baker McKenzie.
A Tasmanian disability group home and respite care provider has been hit with a $1.1 million penalty after admitting it failed to notify the NDIS Quality and Safeguards Commission about reportable incidents 474 times.
Mining contractor BUMA, which was hired to provide services at the Commodore coal mine in Queensland, has come out on top in a $30 million dispute with the mine’s owner, Genuity.
A banking and finance partner has joined Norton Rose Fulbright’s Melbourne office after 15 years at Corrs Chambers Westgarth.
Gaming company Light & Wonder will pay $190 million to settle Aristocrat’s litigation in Australia and the United States alleging it misappropriated trade secrets in developing two poker machines.
The University of NSW has been hit with a $211,200 penalty after admitting to “systemic” underpayments of casual staff at its business school.
Otsuka Pharmaceuticals has asked the High Court to overturn a decision revoking its Abilify patent extension, saying the ruling, which limited the extension-of term scheme to active substances only, will “lead to a groundswell of court proceedings”.
German drug maker Merck KGaA is fighting US drug company Merck Sharp & Dohme over the alleged use of the ‘Merck’ mark in Australia, five years after their intellectual property spat was settled.
Orders proposed by Apple after a judge’s finding that the digital giant and rival Google engaged in anti-competitive conduct would “rob the court’s findings of their detail, their efficacy and their bite”, Epic Games has said.